Darwin Global Management »

Nuvalent Inc-a shares owned by Darwin Global Management

Quarter-by-quarter ownership of Nuvalent Inc-a (NUVL) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Nuvalent Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Nuvalent Inc-a held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nuvalent Inc-a by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $4.2M 58k 73.59

More positions owned by Darwin Global Management

Ambrx Biopharma
Tg Therapeutics (TGTX)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Vaxcyte (PCVX)
Springworks Therapeutics (SWTX)
Nuvalent Inc-a (NUVL)

View all positions for Darwin Global Management

Top funds holding Nuvalent Inc-a

Deerfield Management Company
Paradigm Biocapital Advisors
Vanguard Group
Perceptive Advisors
Fairmount Funds Management
Commodore Capital
Boxer Capital
T. Rowe Price Associates
Wellington Management Company
D. E. Shaw & Co
Lord, Abbett & Co
Ikarian Capital
Soleus Capital Management
Fred Alger Management
Dimensional Fund Advisors

View all funds holding Nuvalent Inc-a